Literature DB >> 19396568

The effects of neoadjuvant chemotherapy and chemo-radiation therapy on MRI staging in invasive bladder cancer: comparative study based on the pathological examination of whole layer bladder wall.

Kazushige Nishimura1, Chisato Fujiyama, Keiji Nakashima, Yuji Satoh, Yuji Tokuda, Jiro Uozumi.   

Abstract

OBJECTIVE: We evaluated the correlation of radiological findings obtained by MRI study with pathological diagnosis in invasive bladder cancer treated with neoadjuvant chemotherapy, with or without radiation. DESIGN, SETTING, AND PARTICIPANTS: Twenty-seven patients, who underwent total or partial cystectomy for invasive bladder tumors, were enrolled into the present study. Eight cases had received neoadjuvant chemotherapy following the staging biopsy (group A), ten cases had received chemo-radiation therapy following the staging biopsy (group B), and nine cases had received preoperative staging biopsy alone (group C). As a final treatment, 12 of the 27 patients underwent total cystectomy and the other 15 patients underwent partial cystectomy. MRI was conducted prior to total or partial cystectomy in each case. The pathological stage was assessed by histological examination of the entire layer of the bladder wall. RESULTS AND LIMITATIONS: Tumor stage assessed by MRI was consistent with pathological findings in 16 of the 27 cases (59.3%), while MRI produced over-staging in 7 cases and under-staging in 4 cases. The accuracy of staging was 75.0, 30.0, and 77.8% in groups A, B, and C, respectively. The accuracy of MRI staging in group B was lower than that in group C (P < 0.05). There was no difference in the accuracy of MRI staging between groups A and C.
CONCLUSION: MRI is useful for the staging of bladder cancer. However, care needs to be taken when staging invasive bladder tumors treated with neoadjuvant chemo-radiation therapy, because inflammatory infiltrations and/or fibrous changes caused by the chemotherapy or chemo-radiation therapy make precise staging with MRI difficult.

Entities:  

Mesh:

Year:  2009        PMID: 19396568     DOI: 10.1007/s11255-009-9566-5

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  12 in total

Review 1.  Bladder cancer staging.

Authors:  A D MacVicar
Journal:  BJU Int       Date:  2000-07       Impact factor: 5.588

2.  Efficacy of gadolinium-diethylenetriaminepentaacetic acid-enhanced magnetic resonance imaging for differentiation between superficial and muscle-invasive tumor of the bladder: a comparative study with computerized tomography and transurethral ultrasonography.

Authors:  M Tachibana; S Baba; N Deguchi; S Jitsukawa; M Hata; H Tazaki; A Tanimoto; Y Yuasa; K Hiramatsu
Journal:  J Urol       Date:  1991-06       Impact factor: 7.450

3.  Dynamic MRI of bladder cancer: evaluation of staging accuracy.

Authors:  Aylin Tekes; Ihab Kamel; Khursheed Imam; Gilberto Szarf; Mark Schoenberg; Khurram Nasir; Richard Thompson; David Bluemke
Journal:  AJR Am J Roentgenol       Date:  2005-01       Impact factor: 3.959

4.  Postirradiation changes in the pelvis: assessment with MR imaging.

Authors:  K Sugimura; B M Carrington; J M Quivey; H Hricak
Journal:  Radiology       Date:  1990-06       Impact factor: 11.105

5.  Bladder wall morphology: in vitro MR imaging-histopathologic correlation.

Authors:  Y Narumi; T Kadota; E Inoue; K Kuriyama; T Horinouchi; K Kasai; H Maeda; M Kuroda; T Kotake; S Ishiguro
Journal:  Radiology       Date:  1993-04       Impact factor: 11.105

6.  Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging.

Authors:  B Kim; R C Semelka; S M Ascher; D B Chalpin; P R Carroll; H Hricak
Journal:  Radiology       Date:  1994-10       Impact factor: 11.105

7.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Authors:  H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

8.  Bladder tumors: staging with gadolinium-enhanced oblique MR imaging.

Authors:  Y Narumi; T Kadota; E Inoue; K Kuriyama; M Fujita; N Hosomi; Y Sawai; M Kuroda; T Kotake; C Kuroda
Journal:  Radiology       Date:  1993-04       Impact factor: 11.105

9.  Bladder tumor staging: comparison of conventional and gadolinium-enhanced dynamic MR imaging and CT.

Authors:  A Tanimoto; Y Yuasa; Y Imai; M Izutsu; K Hiramatsu; M Tachibana; H Tazaki
Journal:  Radiology       Date:  1992-12       Impact factor: 11.105

10.  Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer.

Authors:  B Ph Schrier; M Peters; J O Barentsz; J A Witjes
Journal:  Eur Urol       Date:  2006-01-31       Impact factor: 20.096

View more
  9 in total

1.  Editorial comment.

Authors:  Michele Pavone-Macaluso
Journal:  Int Urol Nephrol       Date:  2009-12       Impact factor: 2.370

2.  Improving bladder cancer imaging using 3-T functional dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Huyen T Nguyen; Kamal S Pohar; Guang Jia; Zarine K Shah; Amir Mortazavi; Debra L Zynger; Lai Wei; Daniel Clark; Xiangyu Yang; Michael V Knopp
Journal:  Invest Radiol       Date:  2014-06       Impact factor: 6.016

3.  Non-invasive quantification of tumour heterogeneity in water diffusivity to differentiate malignant from benign tissues of urinary bladder: a phase I study.

Authors:  Huyen T Nguyen; Zarine K Shah; Amir Mortazavi; Kamal S Pohar; Lai Wei; Guang Jia; Debra L Zynger; Michael V Knopp
Journal:  Eur Radiol       Date:  2016-08-23       Impact factor: 5.315

Review 4.  Multiparametric magnetic resonance imaging for bladder cancer: a comprehensive systematic review of the Vesical Imaging-Reporting and Data System (VI-RADS) performance and potential clinical applications.

Authors:  Denis Séguier; Philippe Puech; Ronald Kool; Léa Dernis; Héléna Gabert; Wassim Kassouf; Arnauld Villers; Gautier Marcq
Journal:  Ther Adv Urol       Date:  2021-08-25

Review 5.  Imaging in Localized Bladder Cancer: Can Current Diagnostic Modalities Provide Accurate Local Tumor Staging?

Authors:  Sandeep Gurram; Akhil Muthigi; Jillian Egan; Lambros Stamatakis
Journal:  Curr Urol Rep       Date:  2019-11-28       Impact factor: 3.092

6.  FDG-PET/CT for response evaluation of invasive bladder cancer following neoadjuvant chemotherapy.

Authors:  E E Fransen van de Putte; E Vegt; L S Mertens; A Bruining; K Hendricksen; M S van der Heijden; S Horenblas; B W G van Rhijn
Journal:  Int Urol Nephrol       Date:  2017-07-03       Impact factor: 2.370

7.  Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer.

Authors:  K M Patel; K E van der Vos; C G Smith; F Mouliere; D Tsui; J Morris; D Chandrananda; F Marass; D van den Broek; D E Neal; V J Gnanapragasam; T Forshew; B W van Rhijn; C E Massie; N Rosenfeld; M S van der Heijden
Journal:  Sci Rep       Date:  2017-07-17       Impact factor: 4.379

Review 8.  Contemporary best practice in the use of neoadjuvant chemotherapy in muscle-invasive bladder cancer.

Authors:  Gautier Marcq; Edouard Jarry; Idir Ouzaid; Jean-François Hermieu; François Henon; Jean-Christophe Fantoni; Evanguelos Xylinas
Journal:  Ther Adv Urol       Date:  2019-01-28

9.  Radiomics-guided therapy for bladder cancer: Using an optimal biomarker approach to determine extent of bladder cancer invasion from t2-weighted magnetic resonance images.

Authors:  Yubing Tong; Jayaram K Udupa; Chuang Wang; Jerry Chen; Sriram Venigalla; Thomas J Guzzo; Ronac Mamtani; Brian C Baumann; John P Christodouleas; Drew A Torigian
Journal:  Adv Radiat Oncol       Date:  2018-05-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.